STOCK TITAN

BioLineRx Ltd. (BLRX) SEC Filings, Mar-Apr 2026

BLRX NASDAQ

BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.

The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.

Rhea-AI Summary

BioLineRx Ltd. director Yan Shaoyu has filed an initial Form 3 insider report. The data shows no reported transactions, with buy, sell, acquire, and dispose counts all at zero. The filing also lists no derivative positions and no holding entries in this snapshot.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
insider
-
Rhea-AI Summary

BioLineRx Ltd. director Sandra Panem filed an initial ownership report showing multiple employee stock options to buy Ordinary Shares. The options cover blocks such as 199,800 shares at an exercise price of $0.356 and 1,080,000 shares at $0.085, with expirations between 2026 and 2034.

Footnotes state that earlier grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant left 856,200 options vested at appointment and 1,198,800 options scheduled to vest in seven equal quarterly installments, subject to her continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
insider
-
Rhea-AI Summary

BioLineRx Ltd. director Raphael Hofstein filed an initial ownership report showing he holds several employee stock options over the company’s ordinary shares. This Form 3 does not report new purchases or sales, but lists option grants previously awarded under the company’s 2003 Amended and Restated Share Incentive Plan.

The disclosed positions include options exercisable at prices such as $0.8370, $0.9200, and as low as $0.0520 per share, with expiration dates ranging from July 2026 to August 2034. Footnotes state that most grants are already fully vested, while a large grant covering 2,055,000 underlying shares at $0.0520 has 856,200 options vested and 1,198,800 scheduled to vest in seven equal quarterly installments, contingent on his continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
insider
Rhea-AI Summary

BioLineRx Ltd. director Dar Rami reported initial holdings of employee stock options over Ordinary Shares. The Form 3 shows several option grants with exercise prices between $0.052 and $0.085, expiring between 2032 and 2034, granted under the 2003 Amended and Restated Share Incentive Plan.

One grant over 2,055,000 underlying shares at an exercise price of $0.052 includes 856,200 options vested as of the appointment date, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
insider
-
Rhea-AI Summary

BioLineRx Ltd. director Molcho Avraham filed an initial ownership report showing a portfolio of employee stock options to acquire Ordinary Shares. The filing lists multiple fully vested grants made between July 2016 and July 2024 under the 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.920 per share and expirations between 2026 and 2034. One large grant covers 2,055,000 underlying shares at an exercise price of $0.052 per share, expiring in 2034, of which 856,200 options were vested on the October 1, 2024 grant date and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
insider
-
Rhea-AI Summary

BioLineRx Ltd. director Cohen Gal Avraham filed an initial ownership report detailing employee stock options over 2,055,000 underlying ordinary shares. These options carry an exercise price of $0.052 per share and expire on August 14, 2034.

The options were granted on October 1, 2024 under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remaining 1,198,800 scheduled to vest in seven equal quarterly installments, subject to continued service. The filing reflects holdings only and does not report any purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
insider
Rhea-AI Summary

BioLineRx Ltd. director Aharon Schwartz filed an initial ownership report showing direct holdings of 3,705,000 Ordinary Shares. He also holds multiple fully vested and time-vested employee stock options under the company’s 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.92 per share and expirations extending through 2034. A large October 2024 grant covers 2,055,000 underlying Ordinary Shares, of which 856,200 were vested at appointment and the remaining 1,198,800 are scheduled to vest in seven equal quarterly installments, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
insider
-
Rhea-AI Summary

BioLineRx Ltd. filed an Amendment No. 1 to its Form 20-F for the fiscal year ended December 31, 2025. The amendment is limited to correcting the date referenced in the consent of its independent auditor, Kesselman & Kesselman, a member firm of PwC, filed as Exhibit 15.1.

Updated CEO and CFO certifications under Sections 302 and 906 of the Sarbanes-Oxley Act are included as new exhibits, as required for amendments. All other disclosures in the original annual report remain unchanged, and the amendment does not update events after the original filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
annual report
-
Rhea-AI Summary

BioLineRx Ltd. Chief Executive Officer Philip A. Serlin filed an initial ownership report detailing his equity position. He directly holds 5,131,800 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with exercise prices ranging from $0.2640 down to $0.0450, expiring between 2026 and 2033. Several option grants are fully vested, while the most recent grant includes options that will vest in quarterly installments, subject to his continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
insider
Form 6-K
Rhea-AI Summary

BioLineRx Ltd. has begun a first‑in‑human Phase 1/2a study of GLIX1, an oral, first‑in‑class TET2 activator, for recurrent and progressive glioblastoma and other high‑grade glioma. GLIX1 aims to selectively disrupt DNA damage repair in cancer cells while sparing healthy tissue.

The Phase 1 portion is expected to enroll up to 30 patients to determine a maximum tolerated or recommended dose based on safety, pharmacokinetics/pharmacodynamics and early efficacy, with initial data anticipated in the first half of 2027. The Phase 2a expansion will test GLIX1 in multiple tumor cohorts and combinations, including with standard treatments such as PARP inhibitors.

The trial is led by world‑recognized GBM investigators at NYU Langone Health, Northwestern University and Moffitt Cancer Center, under a collaboration with Hemispherian AS. BioLineRx also highlights its approved product APHEXDA for stem cell mobilization in multiple myeloma and an ongoing Phase 2b study of motixafortide in metastatic pancreatic cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.10%
Tags
current report

FAQ

How many BioLineRx Ltd. (BLRX) SEC filings are available on StockTitan?

StockTitan tracks 42 SEC filings for BioLineRx Ltd. (BLRX), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BioLineRx Ltd. (BLRX)?

The most recent SEC filing for BioLineRx Ltd. (BLRX) was filed on November 18, 2026.